Managed by Brandon Capital, Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries originating from member research organisations, providing both capital and expertise to guide the successful development of new therapies.
Brandon BioCatalyst is a unique collaboration of investors, CSL, government and more than 50 leading medical research institutes and hospitals united by a single purpose: generating cutting edge, next generation medical therapies and technologies to improve health and save lives.
50+ Medical research institutes and hospitals
NSW Government Health
Government of South Australia
Western Australian Government
Ministry of Business, Innovation & Employment (MBIE) NZ
The John Curtin School of Medical Research (JCSMR) is a multi-disciplinary institute. We excel in ground-breaking medical research in Cancer Biology; Immunology and Infectious diseases; Genomics; and Neuroscience.View
Mater Research is a recognised leader in medical research. Our bench to bedside philosophy sees us working across Mater Health’s hospitals and health services, The University of Queensland, and the world-class Translational Research Institute (TRI).View
The Telethon Kids Institute is the largest research institute in Western Australia, with a bold vision to improve the health and development of children through excellence in research. Focused on translation, the Institute’s researchers and clinicians work closely, together with our research collaborators across Australia and around the world, to maximise research impact. They have extensive experience in coordinating technology and pharmaceutical interventions – including industry-sponsored trials – across a variety of diseases affecting childrenView
Brandon Capital manages Brandon BioCatalyst, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies.Brandon Capital website
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.